Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma

NCT04983407 is registered in ClinicalTrials.gov with Aravive, Inc. as lead sponsor.

NCT NCT04983407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04983407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Aravive, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
July 28, 2021
Completion date
August 14, 2023
Enrollment
34 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma